Level 1: eLearning

ESMIT Live Webinar series

Easily accessible from the comfort of your own home – Get the best of ESMIT education without travelling!

Live webinars are condensed pieces of live, high-quality education which include theoretical presentations, case-based teachings, and a lot of interaction between our facilitators and our participants.

Through this series of free live webinars, experts in the field of nuclear medicine will share their knowledge about various topics in an interactive online setting accessible from all over the world.

  • All webinars are written and facilitated in English.
  • Each live webinar is limited to 250 participants.
  • After the live event has taken place, the recording will be accessible for free on our eLearning platform. You can access the eLearning materials by logging in with your personal username and password or easily creating a new confidential account.
  • Participants of the live webinar series will receive CME credits.

 

 

Upcoming ESMIT Live Webinars 

 

ESMIT Live Webinar Mini-Series
incl. Case Reading Sessions

“Advanced Hybrid Imaging Techniques Including Therapy in Paediatric Patients (Children and Young Adults)”

 December 9 – 11, 2020

 

For more information and to register, simply click on the webinar of your choice:


December 9, 2020 13:00 - 15:00 (CET):
Hybrid Imaging in Paediatrics: From Equipment to Clinical Application - Register now!

 
Speakers: Lorenzo Biassoni
  Alessandra Zorz
Moderator: Pietro Zucchetta
Target audience: Medical specialists and physicians in-training (residents) with special interest in paediatric nuclear medicine and paediatric multimodality imaging
 


Content

The first webinar of the ESMIT Paediatrics Mini-series will refresh your knowledge on hybrid imaging equipment and will highlight the importance of the use of SPECT and SPECT/CT for musculoskeletal imaging in Paediatrics.
In terms of pathology the focus will be on the limping child, trauma, infection, inflammation and other benign bone & joint diseases.

 

Schedule

Lecture 1 (25 mins): Equipment refresher – SPECT/CT A. Zorz
Lecture 2 (25 mins): Equipment refresher – PET/CT and PET/MR A. Zorz
Case reading 1 (40 mins): SPECT/CT and PET/CT over SPECT and PET L. Biassoni
Discussion and Q&A

 

Faculty

  • Lorenzo Biassoni – Great Ormond Street Hospital for Children NHS Foundation Trust, London/UK
  • Alessandra Zorz – Veneto Institute of Oncology IOV – IRCCS, Padova/Italy
  • Pietro Zucchetta – University Hospital, Padova/Italy

 

CME Accreditation

An application has been made to the UEMS EACCME for CME accreditation of this even

 


December 10, 2020 - 12:30 - 15:00 (CET):
Multimodality Imaging in Paediatrics: Bone Malignancies and Nephro-Urologic Diseases - Register now!

 
Speakers: Francesco Ceci
  Isabel Roca
Moderator: Paola Anna Erba
Target audience: Medical specialists and physicians in-training (residents) with special interest in paediatric nuclear medicine and paediatric multimodality imaging
 


Content

The second webinar of the ESMIT Paediatrics Mini-series will cover the use of PET/CT and PET/MR in Paediatric bone malignancy, as well as the role of multimodality imaging in the work-out of nephro-urological Paediatric diseases with a focus on childhood urinary tract infections, evaluation of the dilated urinary tract and other frequent congenital anomalies.

 

Schedule

Lecture 1 (25 mins):  PET/CT and PET/MR for bone disease F. Ceci
Case reading 1 (40 mins) F. Ceci
Lecture 2 (25 mins): Nephro-urologic scintigraphy and multi-modality imaging I.Roca
Case reading 2 (40 mins) I. Roca
Discussion, Q&A

 

Faculty

  • Francesco Ceci – University of Turin, Turin/Italy
  • Paola Anna Erba – University of Pisa Medical School, Pisa/Italy
  • Isabel Roca – Hospital Universitari Vall d’Hebron, Barcelona/Spain

 

CME Accreditation

An application has been made to the UEMS EACCME for CME accreditation of this even

 


December 11, 2020 - 10:30 - 12:30 (CET):
Theranostics in Neuroblastoma - Register now!

 
Speakers: Arnoldo Piccardo
  Soňa Balogova
  Kateřina Táborská
Moderator: Paola Anna Erba
Target audience: Medical specialists and physicians in-training (residents) with special interest in paediatric nuclear medicine and paediatric multimodality imaging
 

Content

This webinar, the 3rd of the ESMIT Paediatrics Mini-series dedicated to the application of multimodality imaging in Paediatrics, will consolidate basic knowledge on Neuroblastoma, covering common imaging protocols with tips for patient preparation. In addition, knowledge will be provided on the selection of patients for treatment with iodine-131 MIBG as well as on the practical aspects related to the phase of treatment administration and patients’ follow-up.

 

Schedule

Lecture 1 (25 mins): Neuroblastoma SPECT/CT and PET/CT A. Piccardo
Lecture 2 (25 mins):  Neuroblastoma therapy with 131I-MIBG. S. Balogova
Case reading 1 (40 mins) K. Táborská
Discussion, Q&A

 

Faculty

  • Soňa Balogova – Comenius University, Bratislava/Slovakia
  • Paola Anna Erba – University of Pisa Medical School, Pisa/Italy
  • Arnoldo Piccardo – Galliera Hospital, Genoa/Italy
  • Kateřina Táborská – Charles University and Motol University Hospital, Prague/Czech Republic

 

CME Accreditation

An application has been made to the UEMS EACCME for CME accreditation of this even

 

 

 

Past ESMIT Live Webinars 

The recordings of the following webinars are available on the ESMIT eLearning Platform. Please note that CME credit may be earned for live webinars only. The archived versions of our webinars are not eligible for CME credit.


FDG PET and Structural MRI in Alzheimer and Dementia

June 10, 2020 – 12:00 (CEST)

 
Speaker: Diego Cecchin
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 

Content

This webinar will show typical 18F-FDG patterns of brain hypometabolism in the context of neurodegenerative disease and in particular regarding Alzheimer disease (AD) and fronto-temporal dementia (FTD). Moreover the talk will discuss main structural (MRI) alterations in neurodegeneration with particular attention to AD and FTD. Common (combined or not) hypometabolism and structural alterations will be presented using clinical 18F-FDG PET/MR cases. Finally proteinopaties concerning AD and FTD will be briefly discussed.

 

Learning objectives

  • Recognize common structural signs of neurodegeneration in MRI
  • Recognize common patterns of hypometabolism in 18FDG PET in AD and FTD
  • Understand which proteinopaty underlie AD and FTD

 

Suggested readings

  • A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
    Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.Neurology. 2016 Aug 2;87(5):539-47. doi:10.1212/WNL.0000000000002923. Epub 2016 Jul 1.
    PMID: 27371494
  • Alzheimer’s disease.
    Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM.Lancet. 2016 Jul 30;388(10043):505-17.
    doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24.
    PMID: 26921134 Review.
  • FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease.
    Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S.Brain. 2007 Oct;130(Pt 10):2616-35.
    doi: 10.1093/brain/awm177. Epub 2007 Aug 18.
    PMID: 17704526


Principles and Indications for Stress MPS

June 10, 2020 – 14:00 (CEST)

 
Speakers: Alessia Gimelli
Eliana Reyes
Moderator: Christoph Rischpler
 

Content

This webinar introduces the basic principles that govern the clinical applications of stress MPS. The indications for MPS are discussed in the context of contemporary imaging technology and protocols, including the use of solid-state gamma-camera systems, the practicalities of regadenoson stress, and the added value of quantitative myocardial perfusion

 

Learning objectives

At the end of this webinar, participants should be able to:

  • Understand the principles underlying the use of MPS for the assessment of coronary artery disease
  • Appreciate the current indications for stress MPS
  • Become familiar with imaging & stress MPS protocols and their importance in clinical practice and service delivery standardisation
  • Recognise the effect of the most advances in stress MPS on clinical practice


Pitfalls and Artefacts in Prostate Cancer PET Imaging

June 12, 2020 – 14:00 (CEST)

 
Speaker: Paolo Castellucci
Moderators: Francesco Ceci
Patrick Pilkington
Target audience: Nuclear medicine physicians, urologist, radiation oncologist, residents
 

Content

In this live webinar we discuss pitfalls, different biodistribution and artefacts for PET/CT imaging in Pca. The lecture will focus on 68Ga-PSMA and 18F-PSMA PET and Fluciclovine PET. Clinical cases will be provided to support the lecture.

 

Learning objectives

  • To understand the different biodistribution among different PSMA variants
  • To understand possible sources of pitfall in PSMA imaging, both considering false positive and false negative findings
  • To introduce the basic concepts and the most common pitfalls in Fluciclovine PET

 

Suggested readings

  • Sheikhbahaei S,  et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117-36. 39.
  • Rischpler C,  et al. 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine. 2018;59(9):1406-11.
  • Rauscher I, et al. Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2019.
  • Nanni C, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0. Eur J Nucl Med Mol Imaging. 2020;47(3):579‐591


Molecular Imaging in Dementia with Parkinsonism

July 9, 2020 – 12:00 (CEST)

 
Speaker: Silvia Morbelli
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 

Content

The talk will discuss the clinical use of brain PET and SPECT in Parkinson’s disease (PD) and atypical parkinsonisms associated with dementia. Both the clinical Utility Molecular Imaging in facilitating the differential diagnosis of common forms of parkinsonism as well as its role in the risk stratification of these patients. Accordingly studies on dementia with lewy bodies (DLB), PD, progressive supranuclear palsy (PSP) syndromes, and corticobasal syndrome (CBS) we’ll be discussed. Aspects related to the role of brain PET and SPECT in prodromal stages of disease will be coverd.

 

Learning objectives

  • To learn about the clinical utility of  FDG-PET and DAT SPECT  to support the diagnosis of parkinsonian syndromes associated with dementia
  • To understand the role of molecular imaging in predicting the risk of convension to dementia in patients with parkinsonism and in particular in PD patients.
  • To appreciate the added value of molecular imaging in prodromal stages of DLB and PD

 

Suggested readings

  • Nobili F, Arbizu J, Bouwman F, Drzezga A, Filippi M, Nestor P, et al. EAN-EANM recommendations for the use of brain 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 20181
  • Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545
  • KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J Neural Transm. 2018;125(4):615–650. doi: 10.1007/s00702-017-1821-9
  • Research criteria for the diagnosis of prodromal dementia with Lewy bodies. McKeith IG, Ferman TJ, et al ; prodromal DLB Diagnostic Study Group. Neurology. 2020 Apr 28;94(17):743-755.
  • Morbelli, S., Esposito, G., Arbizu, J. et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes


SPECT-MPI: Protocols, Pearls and Pitfalls

July 9, 2020 – 14:00 (CEST)

 
Speakers: Antti Saraste
Fabien Hyafil
Moderator: Christoph Rischpler
Target audience: Nuclear medicine physicians, cardiologists, physicists, radiopharmacists
 

 

Content

  • Implementing gated SPECT
  • CAD diagnosis SPECT/CT
  • Viability detection SPECT
  • Artifacts
  • Challenges in MPI: pearls and pitfalls

 

Learning objectives

The aim of this webinar will be to give an overview on how to perform, analyze and write reports for SPECT-MPI.


How to report PSMA PET in Prostate Cancer. An Introduction to E-PSMA: The EANM standardized Reporting Guidelines v1.0 for PSMA PET/CT

July 10, 2020 – 14:00 (CEST)

 
Speaker: Francesco Ceci
Moderator: Patrick Pilkington
Target audience: Nuclear medicine physicians, urologists, radiation oncologists, residents
 

Content

This live webinar will discuss the standardization of the clinical report for PSMA PET in Prostate Cancer, in according to the most recent guidelines released by the EANM.

 

Learning objectives

This lecture will have as main objective to provide an overview about the new guidelines for reporting PSMA PET as suggested by the EANM. The audience will be introduced to the structured report for PSMA PET and will understand how to provide a report in accordance to EANM guidelines. Finally, hints and tips will be given regarding how to avoid common mistakes in PSMA PET images reading and how to interpret the most common findings that represent potential pitfalls.

 

Suggested readings

  • E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2020. [Under Review].
  • Eiber M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT [published correction appears in J Nucl Med. 2018 Jun;59(6):992]. J Nucl Med. 2018;59(3):469‐478.
  • Ceci, F., Fanti, S. Standardisation of PSMA images interpretation: why do we need it?. Clin Transl Imaging 6, 331–333 (2018). https://doi.org/10.1007/s40336-018-0301-z.


Amyloid PET in Dementia

September 10, 2020 – 12:00 (CEST)

 
Speaker: Henryk Barthel
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists

Content

This webinar will discuss the available tracers to image amyloid pathology by PET, and the respective image analysis techniques. It will also provide the current clinical indications for amyloid imaging, together with future trends in this regard. Also, some amyloid PET imaging cases will be discussed.

 

Learning objectives

The aim of this webinar is

  • To provide an overview on the different amyloid PET tracers/respective analysis rules
  • To teach current appropriate use criteria for amyloid PET imaging
  • To increase amyloid PET reading confidence

 

Faculty

  • Univ.-Prof. Dr. med. Henryk Barthel – Department of Nuclear Medicine, University of Leipzig/Germany
  • Dr. Elsmarieke van de Giessen – Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam/Netherlands

 

Suggested readings

  • Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH; Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce. Alzheimers Dement. 2013 Jan;9(1):e-1-16.
  • SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.  Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, Mathis CA, McConathy J, Nordberg A, Sabri O, Seibyl JP, Stokes MK, Van Laere K. J Nucl Med. 2016 Aug;57(8):1316-22
  • Yes we can analyse amyloid images – Now What? Barthel H, Seibyl J, Sabri O. Eur J Nucl Med Mol Imaging. 2017 May;44(5):822-824.
  • Proven validity and management impact of amyloid imaging in Alzheimer’s disease-repetita juvant. Barthel H, Arbizu J, Drzezga A, Garibotto V, Lammertsma AA, Morbelli S; EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging. 2020 Mar 4. doi: 10.1007/s00259-020-04742-w


PSMA Imaging in Advanced Prostate Cancer. From PET to PSMA Radio-Ligand Therapy

September 11, 2020 – 12:00 (CEST)

Speaker: Benedikt Feuerecker
Moderators: Francesco Ceci
Patrick Pilkington
Target audience: Nuclear Medicine Physicians, urologist, radiation oncologist, oncologist, residents

 

Content

In this live webinar we will discuss the role of PSMA PET imaging in advanced prostate cancer. More in detail this lecture will give recommendations regarding the proper selection of patients suitable for PSMA based radioligand therapy.

 

Learning objectives

  • To understand how to interpret PSMA PET scans in advanced metastatic patients
  • To understand which PET parameters should be taken into consideration prior to radio-ligand therapy
  • To understand possible sources of error (e.g. PSMA negative lesions or missmatch between PSMA and FDG PET)

 

Faculty

  • Dr. Benedikt Feuerecker – Department of Nuclear Medicine, Klinikum rechts der Isar, Munich/Germany
  • Francesco Ceci MD PhD – Assistant Professor, University of Turin/Italy
  • Dr. Patrick Pilkington – Department of Nuclear Medicine, Hospital Universitario 12 de Octubre, Madrid/Spain

 

Suggested readings

  • Kratochwil C, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536‐2544.
  • Hofman MS, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825‐833.
  • Kratochwil C, Haberkorn U, Giesel FL. Radionuclide Therapy of Metastatic Prostate Cancer. Semin Nucl Med. 2019;49(4):313‐325.
  • Fendler WP, et al. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(24):7448‐7454. doi:10.1158/1078-0432.CCR-19-1050


Nuclear Medicine Diagnostics and Monitoring in Large Vessel Vasculitis and Cardiac Amyloidosis

September 11, 2020 – 14:00 (CEST)

Speakers: Olivier Gheysens  
Riemer Slart
Moderator: Christoph Rischpler
Target audience: Nuclear medicine physicians, residents NM, imaging-cardiologists, imaging-rheumatologists

 

Content

Large vessel vasculitis (LVV) is a disease characterized by inflammation of the larger arteries with two main variants Takayasu arteritis (TA) and giant cell arteritis (GCA). Both entities differ in terms of age onset, ethnic distribution and affected vascular territories, but share overlap in the histopathology of inflammatory lesions. In addition, GCA belongs to a disease spectrum with polymyalgia rheumatica with both entities often present within the same patient. Nowadays, FDG-PET/CT plays a crucial role in the diagnosis of patients with LVV or the co-existence of LVV and PMR. It is important to early establish the diagnosis of LVV to timely initiate therapy in order to prevent late complications such as stenoses and aneurysms.  Since FDG-PET is a whole-body imaging technique, it provides information of the vessels involved in the disease process and may assist in the differential diagnosis between PMR and other rheumatological disorders such as elderly-onset rheumatoid arthritis based on the inflammatory patterns. In additon to diagnosis, there is emerging evidence that FDG-PET is a suitable modality to assess therapy efficacy which may be important to evaluate novel anti-inflammatory drugs. The introduction of PET/MR may allow simultaneous information on vessel wall inflammation and morphology, which may be advantageous for assessing cranial arteries, but this requires further investigations. Finally, novel tracer development e.g. targeting interleukins may also play a role in the future.

Cardiac amyloidosis (CA), commonly resulting from deposition of misfolded immunoglobulin light chain (AL) or transthyretin (ATTR) protein, is an underestimated cause of heart failure. ATTR has gained increasing attention in recent years and can be divided into a hereditary type (ATTRv) and a wild-type (ATTRwt). Accurate and early diagnosis of heart failure as a result of CA has major implications on prognosis and treatment, using echo and MRI in the first line. Molecular imaging with PET and SPECT nowadays play a critical role in the diagnosis, identification and distinction between ATTR and AL type CA. Bone scintigraphy is an important non-invasive tool to diagnose cardiac amyloidosis due to ATTR (either ATTRv or ATTRwt). Additionally, the innervation agent 123I-MIBG accumulates in vesicles in sympathetic nerve endings close to myocardial cells and the reduced uptake and increased loss reflects myocardial cell damage caused by amyloid. More specific PET-imaging tracers in amyloidosis selectively bind to β-amyloid plaques. Current and new treatments are targeted at reducing the production or stabilisation of the precursor protein or aiming at promoting amyloid removal and thereby aim to stop or slow down further accumulation of CA. Molecular imaging should be able to visualize regression of CA under these new treatment regimens, but data are lacking at this moment. For diagnostic considerations, specific target imaging using hybrid or multimodality techniques such as PET/MR definitely will play a role in the future.

 

Learning objectives 

  • Background information of large vessel vasculitis (LVV)/polymyalgia rheumatica (PMR) and cardiac amyloidosis (CA), including the different types, and it’s disease burden.
  • The role of non-invasive imaging in the diagnostic work-up of LVV and CA.
  • Details of FDG PET/CT in LVV/PMR and bone agent imaging in CA, including imaging protocol, scoring, and interpretation, using the new consensus recommendations.
  • Overview of novel PET imaging in CA. • New therapy approaches for managing patients with LVV/CA

 

Faculty

  • Olivier Gheysens, MD PhD – Department of Nuclear Medicine, Cliniques universitaires Saint-Luc – Brussels/Belgium
  • Riemer H.J.A. Start, MD PhD – Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen/Netherlands
  • Prof. Dr. Christoph Rischpler – Department of Nuclear Medicine, University of Duisburg – Essen/Germany

 

Suggested readings

  • doi: 10.1007/s12350-019-01760-6
  • doi: 10.1007/s12350-019-01761-5
  • doi: 10.1007/s00259-018-3973-8
  • EANM 2018 & 2019 CME LVV and CA


Nuclear Imaging Technology: Where we came from, where we are and where we are heading

October 22, 2020 – 11.00 am (CET)

Speakers: Ian Armstrong Stephan Nekolla
John Dickson Dimitris Visvikis
Moderator: Michel Koole

I.Armstrong

J.Dickson

M.Koole

S.Nekolla

D.Visvikis

Content

Nuclear medicine is a field, which is almost one century old and provides one the oldest integrated approached between diagnostic, therapy and physics. The development of the latter in terms of diagnostic imaging and therapy assessment is the topic of this webinar. In particular, this introduction of “digital” imaging systems created quite some buzz. This webinar provides information where we are coming from, critically reflects on the latest generation of devices and attempts an outlook where we are – or at least – where we could head.
For the PET domain, we give an overview of the development of PET hardware. Focussing in particular on the transition from PMTs to solid-state SiPM technology. This brings substantial improvements to Time of Flight performance, increasing the effective sensitivity of the system.
For the SPECT realm, we will describe the ‘digital’ semiconductor technologies that have been used and are being developed for SPECT applications. Comparisons will be made with traditional scintillation devices to help define if and where these technologies could be used in the future and where traditional analog systems will remain the default.”
So, in summary, as over the past couple of decades there seems to be a new system (in terms of design or multimodality) as well as major technological developments taking place every ten years.
Within this context the webinar will aim at providing a few hints concerning such potential technological evolutions within the current decade.

 

Learning objectives

The aim of this webinar is to provide information on the origins of nuclear medicine and its dedicated imaging hardware, the introduction of hybrid systems, their development cycles since then and finally a critical outlook.

 

Faculty

  • Ian Armstrong, MPhys, Msc, PhD – Central Manchester University Hospitals, Manchester/UK
  • John Dickson, PhD – University College London Hospitals, London/UK
  • Stephan Nekolla, PhD – Klinikum rechts der Isar, Munich/Germany
  • Dimitris Visvikis, PhD – National Institute of Health and Research (INSERM), Brest/France
  • Michel Koole, PhD – KU Leuven, Leuven/Belgium

 

Suggested readings

  • Hutton BF. The origins of SPECT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S3-16. doi: 10.1007/s00259-013-2606-5Sensors for Positron Emission Tomography Applications.
  • Jiang W, Chalich Y, Deen MJ. Sensors for Positron Emission Tomography Applications ; Sensors (Basel). 2019 Nov 17;19(22):5019.
  • Paul Lecoq: Pushing the Limits in Time-of-Flight PET Imaging: https://ieeexplore.ieee.org/document/8049484
  • Suleman Surti et al. : Total Body PET: Why, How, What for? : https://ieeexplore.ieee.org/document/9056798


PET MPI: Tracers, Equipment, Protocols, Flow Quantification, Viability

October 29, 2020 – 11:00 (CET)

Speakers: Mark Lubberink
Roberto Sciagrà
Moderator: Christoph Rischpler
Target audience: Nuclear Physicians with access to a PET facility, willing to begin with cardiac PET.

Content

The course will describe the procedures in cardiac PET, including the execution of cardiac perfusion PET with flow quantification, gated perfusion PET, PET with FDG for viability detection, hybrid imaging with PET/CT or PET/MR.

 

Learning objectives

The aim of the course is to allow a first orientation in the multiple possibilities of PET in the field of cardiac imaging, with particular regard to the implementation of quantitative cardiac PET protocols.

 

Faculty

  • Mark Lubberink, PhD – Department of Surgical Sciences / Nuclear Medicine & PET, Uppsala University Hospital – Uppsala/Sweden
  • Prof. Dr. Roberto Sciagrà – Department of Biomedical, Experimental and Clinical Sciences, University of Florence – Florence/Italy
  • Prof. Dr. Christoph Rischpler – Department of Nuclear Medicine, University of Duisburg – Essen/Germany

 

This website uses cookies. Learn more